Glycocalyx Shedding Biomarkers During Anesthetic Stress: Clinical Relevance and Recent Advances

Abstract

The endothelial glycocalyx is a delicate, carbohydrate-rich layer lining the vascular endothelium, crucial for vascular homeostasis, barrier function, and modulation of inflammatory responses. During anesthetic stress, disruption of the glycocalyx—referred to as glycocalyx shedding—can occur, releasing specific biomarkers detectable in circulation. This review synthesizes recent PubMed-indexed evidence on the science of glycocalyx shedding biomarkers during anesthesia, discusses the underlying mechanisms, and explores their clinical significance for perioperative management. Understanding the role and measurement of these biomarkers holds promise for risk stratification, monitoring, and therapeutics in vulnerable surgical populations.

Introduction

The vascular endothelial glycocalyx serves as a dynamic interface between circulating blood and the vessel wall, regulating vascular permeability, inflammation, and coagulation. Increasingly, attention has focused on its vulnerability to perioperative insults, particularly during anesthetic stress. Anesthesia, encompassing both surgical trauma and pharmacological agents, has been implicated in glycocalyx degradation. The resulting release of glycocalyx components into the bloodstream provides a window for biomarker-based assessment of vascular injury. This article comprehensively reviews the current understanding of glycocalyx shedding biomarkers during anesthetic stress, with an emphasis on clinical implications for anesthesiologists and perioperative physicians.

Epidemiology / Disease Burden

Glycocalyx degradation contributes to adverse perioperative outcomes, especially in high-risk patient groups such as the elderly, those with sepsis, cardiovascular disease, or diabetes. Surgical procedures—particularly major surgeries and those involving cardiopulmonary bypass—are associated with significant glycocalyx shedding, as evidenced by elevated circulating biomarkers. Epidemiological studies reveal that the incidence of endothelial dysfunction is directly correlated with perioperative morbidity and mortality, with glycocalyx shedding serving as an early indicator of vascular injury. The burden is particularly notable in cardiac, vascular, and trauma surgery, where perioperative endothelial dysfunction may predict organ dysfunction and prolonged recovery.

Pathophysiology

The glycocalyx is composed of proteoglycans (such as syndecans and glypicans), glycosaminoglycans (heparan sulfate, chondroitin sulfate, hyaluronan), and associated plasma proteins. Anesthetic stress, including hemodynamic disturbances, inflammatory mediators, ischemia-reperfusion, and exposure to certain anesthetic agents, triggers enzymatic cleavage and shedding of these structures. Matrix metalloproteinases, heparanases, and reactive oxygen species mediate this process. Loss of the glycocalyx compromises endothelial barrier integrity, leading to increased capillary permeability, tissue edema, leukocyte adhesion, and microvascular dysfunction. The resulting release of syndecan-1, hyaluronan, and heparan sulfate into plasma can be quantified as biomarkers of glycocalyx injury.

Risk Factors

Multiple perioperative and patient-specific factors predispose to glycocalyx shedding during anesthesia. These include advanced age, preexisting endothelial dysfunction (e.g., in diabetes, hypertension, atherosclerosis), systemic inflammation, surgical trauma, hypovolemia, and use of certain anesthetic and vasoactive drugs. Prolonged or complex surgeries, major blood loss, cardiopulmonary bypass, and ischemia-reperfusion events further heighten risk. Additionally, hyperglycemia and oxidative stress amplify glycocalyx vulnerability. Recognition of these risk factors is essential for risk stratification and personalized perioperative management.

Clinical Features

Clinically, glycocalyx shedding is a subclinical event, but its consequences manifest as perioperative complications. These include increased capillary leakage, tissue edema, hemodynamic instability, impaired organ perfusion, and subsequent organ dysfunction—particularly acute kidney injury, pulmonary edema, and myocardial injury. Elevated biomarkers of glycocalyx degradation correlate with severity of these complications and can serve as surrogate markers for endothelial injury. Importantly, the temporal kinetics of biomarker release may aid in early identification of patients at risk for adverse outcomes.

Diagnosis

The gold standard for direct visualization of the glycocalyx is currently unavailable in routine clinical practice. Instead, plasma concentrations of syndecan-1, hyaluronan, and heparan sulfate serve as established biomarkers of shedding. Enzyme-linked immunosorbent assays (ELISA) are most commonly used for quantification. Serial measurement of these biomarkers perioperatively can provide dynamic information about endothelial injury. Research is ongoing to standardize reference ranges, establish timing for optimal sampling, and correlate biomarker levels with clinical endpoints. Emerging technologies, such as sidestream dark field (SDF) imaging, offer promise for non-invasive assessment of microvascular glycocalyx in vivo.

Treatment & Management

Management of glycocalyx shedding focuses on prevention and mitigation of further endothelial injury. Strategies include meticulous hemodynamic optimization, avoidance of hypovolemia and hypervolemia, minimizing exposure to high doses of vasopressors, and controlling perioperative inflammation and hyperglycemia. Choice of anesthetic technique and agents may influence glycocalyx integrity, with some evidence suggesting a protective effect of volatile anesthetics and balanced anesthesia. Judicious fluid therapy—favoring balanced crystalloids and albumin over synthetic colloids—has been advocated. Postoperative monitoring of at-risk patients and early intervention for organ dysfunction are critical aspects of care.

Recent Advances / Emerging Therapies

Recent research has focused on pharmacological agents and interventions aimed at stabilizing or restoring the glycocalyx. These include antioxidants, statins, corticosteroids, and agents targeting specific pathways involved in glycocalyx degradation. Recombinant human antithrombin and hydrocortisone have shown promise in experimental models. Additionally, perioperative use of albumin and glycosaminoglycan analogs is under investigation. The development of rapid, bedside assays for glycocalyx biomarkers and advances in non-invasive imaging are poised to transform perioperative risk assessment and individualized patient management.

Guideline Recommendations

While formal guidelines for glycocalyx protection during anesthesia are still evolving, consensus statements emphasize the importance of endothelial protection through goal-directed hemodynamic management, avoidance of excessive fluid shifts, moderation of vasopressor use, and perioperative glucose control. Several perioperative medicine societies recommend ongoing research and integration of glycocalyx biomarkers into risk stratification and clinical trials. Adoption of evidence-based protocols for fluid management and hemodynamic monitoring aligns with the goal of minimizing endothelial injury during anesthesia.

Conclusion

Glycocalyx shedding during anesthetic stress represents a pivotal event in the pathogenesis of perioperative endothelial dysfunction and organ injury. The measurement of circulating glycocalyx degradation products as biomarkers offers a valuable tool for early detection, risk assessment, and potentially targeted intervention. Ongoing research is needed to refine biomarker-based diagnostics, standardize assay methods, and develop effective therapies to protect the glycocalyx. A deeper understanding of these mechanisms will enhance perioperative care and improve outcomes for vulnerable surgical patients.